Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AZD0780 + ezetimibe + bempedoic acid
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This is an investigational oral combination therapy being evaluated for the treatment of dyslipidemia, specifically elevated low-density lipoprotein cholesterol (LDL-C). It consists of three components: - **AZD0780**: An oral, novel compound (mechanism of action not yet publicly detailed) under clinical development by AstraZeneca. - **Ezetimibe**: An inhibitor of intestinal cholesterol absorption, which selectively blocks the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the small intestine, reducing cholesterol uptake. - **Bempedoic acid**: An oral adenosine triphosphate citrate lyase (ACL) inhibitor that lowers LDL-C by inhibiting cholesterol synthesis upstream of HMG-CoA reductase, the target of statins. The combination is being studied in a phase 1 clinical trial in participants with elevated LDL-C to assess its pharmacokinetics, safety, tolerability, and preliminary efficacy. Each component is administered orally as a tablet, and the regimen is positioned for patients needing additional LDL-C lowering beyond current therapies[1][3][5][7].
- Other names
- AZD0780 + ezetimibe + bempedoic acid
02
Targets
ACLY (ATP-citrate synthase)NPC1L1 (Niemann-pick C1-Like 1 transporter)
Beyond the preview
Go deeper on AZD0780 + ezetimibe + bempedoic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AZD0780 + ezetimibe + bempedoic acid.